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1. Introduction 
A successful functioning vascular access is the “lifeline” for a hemodialysis patient.  
Hemodialysis vascular access dysfunction is a major cause of morbidity and mortality in 
hemodialysis patients1-3. Improving vascular access outcomes remains an ongoing challenge 
for nephrologists, vascular access surgeons, and interventionists.  In arteriovenous fistulas 
(AVF) and grafts (AVG), the most common cause of this vascular access dysfunction is 
venous stenosis as a result of neointimal hyperplasia within the peri-anastomotic region 
(AVF) or at the graft-vein anastomosis (AVG) 4,5. There have been few effective treatments 
to-date for venous neointimal hyperplasia in part because of the poor understanding of the 
pathogenesis of venous neointimal hyperplasia.  Central venous catheters (CVC) are prone 
to frequent thrombosis and infection and the treatment of catheter-related bacteremia (CRB) 
remains on ongoing debate 6-8. Therefore, this review will: (1) describe the pathology and 
pathophysiology of hemodialysis access stenosis in AVFs and AVGs, (2) discuss the 
pathogenesis of CRB and catheter thrombosis (3) discuss current and future novel therapies 
for treating venous neointimal hyperplasia, (4) discuss current strategies to treat CRB and 
catheter thrombosis, and (5) suggest future research areas in the field of hemodialysis 
vascular access dysfunction. 
1.1 Types of hemodialysis access 
Successful hemodialysis treatment requires access to the bloodstream to deliver a high 
enough blood flow to achieve an adequate dialysis dose.  There are three primary types of 
hemodialysis vascular access to achieve this goal:  (1) arteriovenous fistula, (2) arteriovenous 
graft, and (3) tunneled central venous catheter.  Each type of access has unique advantages 
and individual problems. 
1.1.1 Arteriovenous fistula 
AVFs are the preferred vascular access for hemodialysis patients, because once mature and 
functional, they require fewer interventions to maintain patency and develop fewer 
infections compared to AVGs 9-13. However, AVFs have higher rates of nonmaturation and 
longer maturation times compared to AVGs, which may lead to prolonged periods of CVC 
dialysis 9,14,15. Recent reports from the United States have shown that up to 60% of AVFs 
never mature adequately to be successfully cannulated for dialysis 16 compared to 20-25 
years ago where the nonmaturation rates in AVFs was approximately 10% 12. 
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1.1.2 Arteriovenous graft 
Arteriovenous grafts (made from polytetrafluoroethylene, a synthetic fluoropolymer of 
tetrafluoroethylene) are advantageous because of short maturation time and relative ease to 
cannulation compared to AVFs 12,17-19.  Until recently, AVGs were the most common access 
used in hemodialysis patients in the Unites States 20.  However, the main disadvantages of 
AVGs are development of recurrent venous stenosis, requiring frequent interventions to 
maintain patency, and graft infection 19,21-24. 
1.1.3 Tunneled central venous catheter 
Tunneled central venous catheters have the advantage of immediate use, multiple sites for 
insertion, and the ability to provide access for hemodialysis for a period of months, permitting 
time for AVF or AVG maturation, in patients who require immediate hemodialysis 19,25-28. 
However, the main disadvantages are the high risks of morbidity and mortality caused by 
infection 7,29-33, catheter thrombosis 19,34-37, and central venous stenosis 37-39.   
2. Epidemiology and clinical significance of hemodialysis vascular access 
dysfunction 
2.1 Epidemiology of hemodialysis vascular access 
Due to reduced AVF use and increased AVG (70% in 1993 40) and catheter use in the United 
States from the mid-1980’s-1990’s, the National Kidney Foundation in 1997, in an effort to 
improve vascular access outcomes, published the first Kidney Disease Outcome Quality 
Initiative (K/DOQI) clinical practice guidelines for vascular access to optimize the care of 
vascular access in hemodialysis patients using evidenced and opinion-based guidelines 41.  
Since these initial clinical practice guidelines have been published, we have seen the creation 
of the Fistula First Breakthrough Initiative (FFBI) 42-45 and two more revised K/DOQI 
clinical practice guidelines and performance measures for vascular access 19,46, which have 
clearly impacted and improved hemodialysis vascular access management.  The most recent 
report from the 2009 United States Renal Data System (USRDS) has showed an AVF 
prevalence of 50% 47, a marked improvement since 2004 (39% AVF prevalence), 2000 (30% 
AVF prevalence), and 1998 (26% AVF prevalence)48 in the United States.  In contrast, AVF 
prevalence in Europe and Japan, reported from the Dialysis Outcomes and Practice Patterns 
Study (DOPPS) has been historically much higher, ranging from 57-91% 20. 
While the K/DOQI guidelines and FFBI have clearly played an instrumental role in meeting 
the initial target goal of 50% AVF prevalence (new goal 66% 19,42), the prevalence of CVC use 
continues to remain between 20-30% in the United States 42. Furthermore, this trend of 
increased catheter use has also been observed in other countries, such as Spain, France, 
Belgium, Germany, and Italy 20. This is likely due to an increase in the number of AVFs that 
have failed to mature for dialysis use in recent years 14,16.   
2.2 Clinical significance and economic implications of hemodialysis vascular access 
dysfunction 
When patients develop vascular access dysfunction, due to an immature AVF or 
thrombosed AVF or AVG, they are often consigned to CVC use for prolonged periods.  
Because dialysis with a catheter is associated with increased morbidity and mortality 49-55, 
CVC use has significant clinical implications such as increased risk of bacteremia which has 
been reported to occur at a frequency ranging from 2.5 to 5.5 episodes per 1000-catheter 
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days 6,56, increased risk of 1-year mortality 49, and 60-70% higher risk of subsequent AVF 
failure 32,57. The cost of treating one CVC-related bacteremia in the United States has been 
estimated to be as high as $45,000 per episode with an average of $22,000 per bacteremic 
episode 58. 
3. Pathology and pathophysiologic mechanisms of hemodialysis vascular 
access dysfunction 
3.1 Pathology of Hemodialysis Vascular Access Stenosis in AVF and AVG 
Venous stenosis that occurs in both AVFs and AVGs is primarily due to neointimal 
hyperplasia.  Venous stenosis in AVGs most frequently arises from the development of 
aggressive neointimal hyperplasia, characterized by (a) the presence of alpha smooth muscle 
actin positive cells myofibroblasts, and microvessels within the neointima, (b) an abundance 
of extracellular matrix components, (c) angiogenesis (neovascularization) within the 
neointima and adventitia, (d) a macrophage layer lining the perigraft region, and (e) an 
increased expression of mediators and inflammatory cytokines such as TGF-β, PDGF, and 
endothelin within the media, neointima and adventitia 59-64.   
While the neointimal hyperplasia in AVFs is similar to AVGs in regards to pathogenesis, the 
venous stenosis that develops in AVFs is highly influenced by the capacity of the vein to 
vasodilitate and vascular injury from surgical technique 65.  In AVFs the two main etiologies 
of failure are an initial failure to mature (nonmaturation) and a subsequent (late) venous 
stenosis 4.  Similar to AVGs, venous neointimal hyperplasia in late AVF stenosis has been 
shown to be composed primarily of alpha smooth muscle actin positive cells, together with 
expression of mediators and cytokines such as TGF-β, PDGF, and endothelin within the 
media and intima of the vein 60,65.  However, recently, the lesion of AVF nonmaturation at 6 
weeks after AVF creation has also been described to have significant neointimal hyperplasia 66.  
3.2 Pathophysiologic mechanisms of neointimal hyperplasia formation in 
hemodialysis access dysfunction 
The pathogenesis of venous neointimal hyperplasia in AVG stenosis and late AVF stenosis 
has been well described and is commonly divided into upstream and downstream events4. 
Upstream events are characterized as the initial events and insults that are responsible for 
endothelial and smooth muscle cell injury, which leads to a cascade of mediators 
(downstream events) that regulate oxidative stress, endothelial dysfunction, and 
inflammation (eventually resulting in venous neointimal hyperplasia).  Upstream events 
that are believed to contribute to the pathogenesis of neointimal hyperplasia include 4,62,67-70: 
(1) surgical trauma at the time of AV surgery, (2) hemodynamic shear stress at the vein-
artery or vein-graft anastomosis, (3) bioincompatability of the AVG, (4) vessel injury due to 
dialysis needle punctures, (5) uremia resulting in endothelial dysfunction, and (6) repeated 
angioplasties causing further endothelial injury.  Downstream events represent the response 
to endothelial (vascular) injury from the upstream events, resulting in the migration of 
smooth muscle cells from the media to the intima and eventually the development of 
neointimal hyperplasia 65.   
The pathogenesis in AVFs that fail to mature (early failure) for dialysis, in contrast to AVG 
and late AVF failure, remains poorly understood.  At a histological level early AVF failure is 
also characterized by aggressive neointimal hyperplasia in both animal and human models, 
seen as early as 1 month in animals 63,71 and 3 months in humans 64,66. The underlying factors 
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(upstream events) which may contribute to early AVF failure, include 4,72-81: (1) small 
diameter sizes in the vein and artery, (2) surgical injury at the time AV fistula placement, (3) 
previous venipunctures, (4) development of accessory veins after surgery, (5) hemodynamic 
shear stress at the AV anastomosis, (6) a genetic predisposition to vascular constriction and 
neointimal hyperplasia, and (7) pre-existing venous neointimal hyperplasia. 
The subsequent sections will focus on the downstream events and three main mechanisms 
responsible for neointimal hyperplasia such as oxidative stress, inflammation, endothelial 
dysfunction, and alternative origins of neointimal-derived cells.   
3.2.1 Oxidative stress 
Many of the upstream mechanisms above (particularly hemodynamic shear stress and 
angioplasty injury) have been documented to result in an increase in the production of free 
radicals and its downstream products nitrotyrosine and latter (peroxynitrate). The latter is a 
potent upregulator of the matrix metalloproteinases (MMPs) 82,83. MMPs are key enzymes 
that cause breakdown of extracellular matrix proteins such as collagen and elastin which 
facilitate the migration of vascular smooth muscle cells (VSMCs) in neointimal hyperplasia 
formation 84.  MMPs, paradoxically, have also been shown to facilitate a beneficial dilatation 
of the feeding artery (through degradation of the internal elastic laminae) in both rabbit and 
mouse AVF models 82,85. Experimental studies of AVGs have demonstrated a differential 
upregulation of MMP-2 at the graft-vein anastomosis, with early expression (9 days) in the 
adventitia and a later expression (19 days) within the intima, supporting the concept of 
cellular migration from the adventitia to the intima 86. Furthermore, linkages between 
hemodynamic shear stress and the expression of oxidative stress markers and cytokines 
have also been described in a porcine model of AVG stenosis 87. Clinical studies of stenotic 
and thrombotic AVGs and AVFs have also demonstrated an upregulation of MMPs 88, and 
have documented the co-localization of oxidative stress markers with inflammatory 
cytokines such as transforming growth factor-beta (TGF-), and platelet-derived growth 
factor (PDGF), within the neointima of both stenotic AVGs and AVFs 60.   
Heme-oxygenase-1 (HO-1) is an important enzyme pathway which has been shown to 
confer protective effects in the vascular endothelium and other organ systems through its 
anti-inflammatory, antioxidant, or antiproliferative actions and properties 89. Experimental 
studies in AVFs have described an increase in both the magnitude of arteriovenous stenosis 
and the frequency of thrombosis following the creation of AVFs in HO-1 knock out mice 
(increased baseline oxidative stress) as compared to wild type animals 90. Furthermore, in 
the HO-1 knockout mice, there was significant induction of MMP-9 expression in the vein at 
1 week compared to wild type mice, suggesting that MMP expression in vascular tissue and 
its deleterious effects with regard to promoting cellular migration may in part be inhibited 
by HO-1.  Clinical studies have demonstrated a higher frequency of AVF failure in patients 
with heme-oxygenase-1 (HO-1) gene polymorphisms with long GT repeats (resulting in 
increased oxidative stress) 73.  
3.2.2 Inflammation 
ESRD is associated with a chronic inflammatory state, characterized by the elevation of 
circulating cytokines and chemokines 91. This inflammation has been proposed to play an 
important role in the initiation and progression of atherosclerosis in ESRD, but may also 
play a significant role in vascular access stenosis.  Support for this paradigm comes from 
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recent work in which uremic mice developed a 2-3 fold greater magnitude of neointimal 
hyperplasia at the arteriovenous anastomosis as compared to non-uremic animals in a 
mouse model of AVF stenosis 92, and a recent study which showed marked upregulation of 
monocyte chemoattractant protein-1 (MCP-1) in the venous segment of AVF compared to 
rats deficient in the MCP-1 gene 93.   
In clinical studies, possible linkages have described the presence of inflammatory cells 
(macrophages and lymphocytes), cytokines such as TGF-ß and insulin-like growth factor-1 
(IGF-1) and the magnitude of neointimal hyperplasia and venous stenosis within stenotic 
AVFs 94.  
Local bioincompatability to synthetic polytetrafluoroethylene (PTFE) material in AVGs 
could also result in local inflammation 95. In vitro studies have demonstrated that 
conditioned media obtained after the interaction of peripheral blood mononuclear cells 
(PBMCs) with PTFE graft material resulted in a significant upregulation of smooth muscle 
cell proliferation as compared to control media 96.  This proliferative response has been 
shown to be attenuated by tumor necrosis-alpha (TNF-) inhibitors 96. Furthermore, the 
presence of macrophages that line PTFE graft material has been described in both 
experimental and clinical AVG stenosis with co-expression of inflammatory cytokines such 
as basic fibroblast growth factor (bFGF) 61,97.  
3.2.3 Endothelial dysfunction 
An intact and functional endothelium is essential for the vein to properly respond to acute 
changes in blood flow that occurs after creation of AVFs and AVGs 98. Nitric oxide (NO) is 
an important mediator responsible for these transformations 99,100. The presence of uremia in 
hemodialysis patients has been shown to exacerbate endothelial dysfunction, possibly 
through the pathways of inflammation and oxidative stress described above 101,102. In the 
specific context of vascular access stenosis, endothelial dysfunction is likely to be 
responsible for the development of pre-existing venous neointimal hyperplasia 77-81, medial 
hypertrophy 77,81 and radial artery intima-media thickening 103-105 that is present even before 
the creation of AVFs in uremic patients. Pre-existing arterial intima-media thickness has 
been correlated with future AVF dysfunction 103. Recently, pre-existing venous neointimal 
hyperplasia has been linked to poor AVF maturation in a small clinical study 77.  
Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of NO synthase and 
has been implicated as an important contributor to endothelial dysfunction in ESRD patients 
106. ADMA is not excreted in ESRD patients and its levels have been reported to be two to six 
times higher in this patient population as compared to non-uremic individuals 107. In a 
recent clinical study in AVFs, patients with elevated ADMA levels at the time of 
percutaneous transluminal angioplasty of an initial AVF stenosis had a significantly 
increased risk of a recurrent AVF stenosis 108.  
3.2.4 Alternative origins of neointimal cells 
Although the traditional paradigm for the pathogenesis of neointimal hyperplasia has 
emphasized the migration of smooth muscle cells from the media to the intima, where they 
proliferate and contribute to the final volume of neointimal hyperplasia, a number of studies 
have reported that following coronary angioplasty or saphenous vein bypass grafting there 
is also a migration of cells (fibroblasts) from the adventitia, through the media, and into the 
intima, where these cells transform into  “myofibroblasts” 109-111. In dialysis access, a number 
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of recent studies in AVGs have supported the concept of a migration of adventitial cells into 
the intima where they contribute to final neointimal volume 59,112.  In addition, recent data 
from several experimental AVF stenosis models have shown that smooth muscle cells in the 
neointima, may in part, originate from bone-marrow-derived cells that bind to the site of 
vascular injury and later differentiate into a smooth muscle cell phenotype in the neointima 
82,113,114. From a therapeutic standpoint, it is likely that better information about the true 
source of neointimal cells will allow for the development of novel therapeutic interventions 
targeting specific cell types. 
3.3 Hemodynamic and vascular remodeling in hemodialysis access dysfunction 
A number of experimental studies have shown that turbulent, low flow, low fluid sheer 
stress are involved in neointimal hyperplasia development 115-119.  High sheer stress has been 
associated with vascular dilatation through inhibition of smooth muscle cell proliferation 
and high levels of nitric oxide release, whereas low sheer stress has been associated with 
smooth muscle cell proliferation and lack of vasodilatation 120-123. Poor hemodynamic 
profiles could be a risk factor for neointimal hyperplasia development and poor venous 
dilatation, and the degree of luminal stenosis is dependent upon both the magnitude of 
neointimal hyperplasia and the capacity for vasodilatation or vasocontriction.  Therefore, a 
significant amount of neointimal hyperplasia and medial hypertrophy may not result in 
luminal stenosis in the presence of adequate vasodilatation, while a small amount of 
neointimal hyperplasia, but with poor vasodilatation, may result in severe venous stenosis 
4,124.  Unfortunately, the factors that are responsible for vascular remodeling are unknown, 
but adventitial angiogenesis and scar formation are hypothesized to play a significant 
role125,126.  Thus, the ideal therapy for vascular stenosis would be an intervention that would 
prevent vascular constriction (adverse remodeling) and neointimal hyperplasia4 
4. Central venous dialysis catheters 
CVC dysfunction and related-infection remains a common cause of morbidity, mortality, 
and high economic costs in treating chronic hemodialysis patients.  This section will provide 
a brief overview of catheter dysfunction and catheter-related infections. 
4.1 Catheter dysfunction 
Catheter dysfunction can occur immediately after placement or in a catheter which has been 
previously functioning without difficulties, and most commonly manifests with low catheter 
blood flows during dialysis or negative arterial pressures on the dialysis machine 6. In more 
severe cases catheter thrombosis is characterized by the inability to aspirate blood from the 
dialysis port 6. Catheter dysfunction which occurs immediately after placement is most 
likely due to placement problems 6.   
Installation of a thrombolytic agent for 30 to 60 minutes is a treatment for catheter 
dysfunction, followed by a second installation if necessary 6. Recently published studies 
have reported varied success rate when treating catheter dysfunction with thrombolytics, 
ranging anywhere between 60-95% 26,28,35,127,128.  When thrombolytic therapy is unsuccessful 
in providing adequate blood flow and adequate dialysis, despite repeated installations, then 
catheter exchange needs to be performed. The current K/DOQI guidelines recommends 
treatment with thrombolytic agents in all catheters with a persistently low blood flow rate 
(<300 ml/min) 19. 
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The current standard of care to prevent catheter thrombosis is installation of an 
anticoagulant in both dialysis ports at the completion of each dialysis session.  In the United 
States, heparin is most commonly used, while in Europe citrate is the more common 
anticoagulant 6.  The studies to-date have shown similar efficacy when comparing citrate to 
heparin for prophylaxis of catheter thrombosis, but with fewer complications of systemic 
bleeding with citrate 129-132. A recent multicenter, randomized-controlled trial has reported 
that use of a thrombolytic, tissue plasminogen activator as a locking solution compared to 
heparin had reduced incidence of catheter dysfunction 34.  
4.2 Catheter-related bacteremia 
Currently, a precise definition for diagnosis catheter-related bacteremia is lacking.  More 
rigorous definitions require a positive blood culture obtained from the catheter and a 
peripheral vein with the quantitative colony count being at minimum four-fold higher from 
the catheter sample 133.  However, recently, the Infectious Disease Society of America has 
recognized the challenges in obtaining peripheral blood cultures from hemodialysis patients 
(e.g. priority for preserving veins and difficult cannulations) and has considered a definition 
of “possible” catheter-related bacteremia as positive blood culture obtained from the 
catheter in a symptomatic patient 134.  
The two main pathways where organisms can gain entry into the blood stream to initiate 
catheter-related bacteremia are intraluminal and extraluminal 135.  Organisms gain entrance 
through the bloodstream extraluminally through contact between the skin surface 
organisms and the external surface of the catheter at the time of catheter placement or 
following catheter placement before healing of the exit site or endothelialization of the 
subcutaneous tunnel 7. Subsequently, the organisms colonize or migrate through the 
intracutaneous exterior tract of the catheter to the tip, allowing for hematagenous dispersion 
of the organisms and leading to catheter-related bacteremia 7. Intraluminal-derived 
infections results from the transfer of organisms from hand contact with the catheter, 
leading to contamination of the internal catheter surfaces 7.  Infection from the extraluminal 
pathway most commonly occurs immediately after catheter insertion, while infections from 
the intraluminal pathway occurs throughout the life of the catheter 7. Irrespective of the 
route of bacterial entry, the bacteria will either adhere to the CVC or become incorporated 
into a fibrin sheath.  Adherence of the bacterial organisms to the CVC initiates a common 
pathway of biofilm production. A mature biofilm is a self-sustaining colony of 
microorganism, guarded by an exopolysaccharide matrix, that is stimulated and secreted by 
the organism and very difficult to eradicate 7,136-140.  
Catheter-related bacteremia can result in devastating complications such as endocarditis, 
osteomyelitis, thrombophlebitis, septic arthritis, spinal epidural abscess, and large atrial 
thrombi 30,31,141-149.  The majority of isolated organisms from catheter-related bacteremia are 
gram-positive organisms (52-84%) with Staph Aureus responsible for the majority of these 
organisms 7,30,31,143,150,151. Gram-negative are isolated in 27-36% of episodes and fungal 
isolated are relatively uncommon (<10%) 141-143,149,152. Therefore, it is important to identify 
catheter-related bacteremia early so treatment can be initiated immediately. 
4.2.1 Treatment of catheter-related bacteremia 
Initial empiric antibiotic treatment should include broad-spectrum coverage for gram-
positive and gram-negative organisms using knowledge of the common organisms and 
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sensitivity patterns that are grown at the dialysis center.  Due to the high prevalence of 
methicillin-resistant Staph Aureus (MRSA), empiric therapy should include coverage for 
MRSA. When the specific organism and antibiotic sensitivities are identified, it is important 
to narrow the antibiotic therapy to prevent the development of drug resistant organisms.  
While the exact duration of antibiotic treatment for catheter-related bacteremia is uncertain, 
the Infectious Disease society of America recommends a 2 week course of antibiotics 153, 
while the K/DOQI guidelines recommends a 3 week course of antibiotics 19. Other 
therapies, which have been used in conjunction with systemic antibiotics, to treat catheter-
related bacteremia are antibiotic catheter locks.  A number of studies have shown that 
antibiotic locks (which may treat the biofilm layer) used in conjunction with systemic 
antibiotics, in tunneled dialysis catheters, have documented a 70% cure rate 30,145,154-156.   
Recent studies have evaluated pharmacologic therapies to prevent catheter-related 
bacteremia. Routine application of topical antibiotic ointments at the CVC exit such as 
mupirocin, povidine-iodine, and polysporin triple ointment has been associated with a 73-
93% reduction in the risk of catheter-related bacteremia 7,151,157-159.  Prophylactic antibiotic 
catheter locks have also recently been evaluated.  A marked reduction in catheter-related 
bacteremia has been reported, ranging from 51-99%, with use of a prophylactic antibiotic 
catheter locking solution 7,160-164.  However, of concern, a recent study has shown emergence 
of gentamicin-resistant organisms after 6 months when using a gentamicin-heparin 
prophylactic catheter lock 165. 
The above strategies for treatment of catheter-related bacteremia apply to patients who are 
clinically stable.  However, catheter removal, in addition to antibiotic therapy, should be the 
treatment of choice when patients: (1) are clinically unstable, (2) have persistent fever for 48 
hours, (3) have evidence of tunnel infection, or (4) develop metastatic infectious 
complications 7. 
5. Translating science to therapies in hemodialysis vascular access 
dysfunction:  from the bench to bedside 
There are currently few if any effective therapies to treat hemodialysis vascular access 
stenosis and neointimal hyperplasia. However, the knowledge obtained in recent years 
regarding the pathology and pathogenesis of vascular access access dysfunction has 
provided a framework for development of therapies that target neointimal hyperplasia and 
vascular stenosis. The purpose of the next section is to (1) describe current therapies for AVF 
and AVG stenosis and (2) novel therapies using localized delivery systems for AVF and 
AVG.  
5.1 Systemic therapies 
Systemic therapies, such as dipyridamole, angiotensin-converting enzyme inhibitors, 
aspirin, and fish oil, from small clinical trials and observational studies have been shown to 
have the potential to block smooth muscle cell proliferation and migration and to prevent 
thrombosis in AVFs and AVGs 166-170.  Most recently, two large randomized controlled trials, 
sponsored by the National Institutes of Health, evaluating anti-platelet agents in AVG and 
AVF to prevent neointimal hyperplasia were published 16,171. In the AVG study, 
dipyridamole and aspirin, modestly reduced the risk of stenosis and improved primary 
unassisted patency 171.  In the AVF study clopidogrel reduced frequency of early thrombosis 
but did not improve AVF suitability defined as cannulation with two needles, minimum 
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dialysis blood flow of 300ml/min, successful use 8/12 dialysis sessions, and use after 120 
days from creation 16.  While these two studies have shown some promising results, the 
clinical significance of these drugs used as standard treatment for hemodialysis access 
stenosis remains questionable. 
Fish oil has been shown to prevent AVG stenosis and thrombosis in one randomized, 
controlled trial 172. Currently, another study evaluating fish oil and AVG stenosis and 
thrombosis is ongoing 173. Other systemic agents, though not tested in randomized clinical 
trials, which have shown potential anti-proliferative effects targeting neointimal hyperplasia 
in CVD or PVD models, include peroxisome proliferation-activated receptor  agonist 174-176, 
sirolimus 177, and imatinib mesylate 176,178,179. 
5.2 Radiation therapy 
Radiation therapy has been hypothesized to be a potential therapy to treat vascular stenosis 
due to its antiproliferative effects and potential beneficial effects of vascular remodeling180-
183. In experimental models, both external beam and endovascular radiation therapy has 
proven effective to reduce neointimal hyperplasia in AVF and AVG 184,185. However, in 
clinical studies, a recent randomized-controlled trial of in AVGs 25 patients showed that 
42% of the radiated AVGs achieved the target lesion primary patency end point at 6 months 
as compared to 0% of the control group (p = 0.015), but this did not translate into an 
improvement in secondary patency at either 6 or 12 months 186.  
5.3 Far infrared therapy 
Infrared radiation is an invisible electromagnetic wave with a longer wavelength than that 
of visible light.  In experimental models, far infrared therapy has been shown to improve 
skin blood flow and endothelial function in cardiovascular disease 187-189.  The rationale for 
far infrared therapy to treat dialysis vascular access stenosis is that the dialysis vascular 
access in patients are located at a superficial site and improving access flow may improve 
vascular access performance.  In the lone clinical study of far infrared in dialysis access in 
AVFs, patients who received far infrared therapy had improved access flows and longer 
unassisted patencies 190. 
5.4 Local drug delivery systems for hemodialysis access 
The rationale behind local delivery of drugs treat hemodialysis vascular access stenosis is 
that (1) AVFs and AVGs could be the ideal clinical model for the use of perivascular 
therapies since these can be easily applied at the time of surgery, (2) perivascular therapies 
preferentially target the “active” adventitia, (3) studies have demonstrated that lipophilic 
molecules when placed over the adventitia rapidly diffuse through all the layers of the 
vessel wall, and (4) small amounts of otherwise toxic drugs can be safely delivered to the 
site of stenosis using the perivascular approach resulting in high local concentrations with 
minimal systemic toxicity 4. The subsequent section will discuss local therapies to treat 
hemodialysis vascular access stenosis from experimental models and clinical studies. 
5.4.1 Drug eluting paclitaxel perivascular wraps 
Experimental studies have previously demonstrated the efficacy of paclitaxel eluting wraps 
in AVG stenosis likely due to anti-proliferative effects 191-193.  In 2007, a large multi-center 
randomized-controlled study, evaluating the use of paclitaxel-eluting mesh wraps, Vascular 
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WrapTM, (Angiotech Pharmaceuticals, Inc.; Vancouver, British Columbia, Canada), was 
initiated to study the effectiveness and safety of this therapy on primary AVG patency 
compared to a standard AVG. However, this study was recently suspended in 2009 
following a data safety monitoring review, due to an imbalance in the incidence of infections 
in one of the arms (either control or treatment). An alternative approach is the use of 
sirolimus eluting COLL-R® wraps (Covalon Technologies Ltd: Mississauga, Ontario, 
Canada). An initial Phase II study demonstrated primary unassisted AVG patency of 75% 
and 38% at 1 and 2 years respectively with these wraps 194. 
5.4.2 Endothelial cell loaded gel foam wraps 
The rationale behind the use of these wraps is that the endothelial cell (in addition to lining 
blood vessels) is also a “bioreactor” which produces a large number of beneficial mediators 
that reduces thrombosis, inflammation, stenosis, and increases lumen diameter.  Initial 
experimental studies have documented a beneficial effect of endothelial cell loaded gel-foam 
wraps in porcine models of AV fistula and graft stenosis 195-198. A recent Phase II study (“V-
HEALTH”) was able to demonstrate technical feasibility and safety in hemodialysis patients 
who received a “Vascugel®” wrap loaded with treated human aortic endothelial cells at the 
time of AVF or AVG placement 97. A phase III multi-center randomized-controlled study 
using the Vascugel® (Pervasis Therapeutics, Inc., Cambridge, MA) wraps in human AVGs is 
currently being designed.   
5.4.3 Vascular Endothelial Growth Factor D (VEGF-D) gene therapy  
In animal models of angioplasty induced restenosis, the delivery of adenoviral particles 
encoding for vascular-endothelial growth factor C to the site of vascular injury has been 
shown to trigger the release of nitric oxide and prostacyclin and reduce neointimal 
hyperplasia 199. Preliminary studies on the use of VEGF-D gene therapy (using a packaged 
adenoviral vector and a biodegradable local delivery device (collar) made of collagen 
wrapped at the venous anastomosis at the time of surgery), “Trinam®” (Ark Therapeutics; 
London, UK), in patients receiving AVGs, have been able to document technical feasibility 
and safety.  A phase III study using this technology was initiated in 2009 but terminated in 
2010 due to poor enrollment. 
5.4.4 Recombinant elastase PRT-201  
PRT-201 (Proteon Therapeutics; Waltham, MA) is a recombinant pancreatic elastase 
topically applied at the outflow vein at the time of surgery access creation which has been 
shown to result in both arterial and venous dilation and an increase in AVF blood flow in 
experimental models 200.  The clinical benefit of this approach is the potential ability to 
enhance AVF maturation (through rapid vascular dilation) and prevent venous stenosis in 
AVGs.  A phase II study using this novel technology is ongoing in the United States 
evaluating this therapy and whether or not it improves primary patency and cumulative 
survival in AVG and AVF, as well as safety.  
5.5 Endovascular stent therapy 
Endovascular vascular therapies (angioplasty or angioplasty with stent placement) remains 
the only true intervention available to treat vascular stenosis.  The main advantage of stent 
therapy after angioplasty is a reduction in adverse remodeling.  In dialysis access, placement 
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of bare metal stents after angioplasty compared to angioplasty 201 alone has been shown to 
improve primary patency 202,203.  However, bare-metal stents have yielded poor results due 
to aggressive development of in-stent restenosis.  In experimental models of dialysis access 
in AVGs, drug-eluting stents have shown to reduce neointimal hyperplasia and improve 
luminal stenosis compared to bare-metal stents 204. However, there are no clinical studies 
evaluating drug-eluting stents in dialysis access to date. 
Stent grafts (covered stents constructed from the same material of AVGs) have received 
recent attention as a therapy for prevention of restenosis due to its ability to prevent elastic 
recoil and inability of the neointimal cells to penetrate the covered barrier. A recently 
published multicenter, randomized controlled, clinical trial showed stent grafts (Bard 
Peripheral Vascular, Tempe, AZ), placed after angioplasty, to treat venous stenosis had 
better primary unassisted patency compared to angioplasty alone 205. This is the only 
treatment to date that has shown to be effective to treat vascular access stenosis in a large, 
randomized, clinical trial. 
5.6 Improving hemodynamics  
Hemodynamic sheer stresses play a significant role in development of neointimal 
hyperplasia 87,112,206,207. Therefore, altering the sheer stress pattern to prevent turbulent, low-
flow, and low-sheer stresses could reduce the development of neointimal hyperplasia.  
Previous clinical data to date to support such an intervention comes from several studies 
evaluating cuffed AVG grafts (“Venaflo”; Bard Vascular, Tempe Arizona) 208-210. In a recent 
randomized control trial evaluating cuffed vs non-cuffed AVG, cuffed AVGs showed better 
primary patency and cumulative survival 211. Finally, results from a newly developed 
anastomotic implant device, “OptiflowTM” (Bioconnect Systems; Ambler, PA), to connect 
the artery and vein in AVFs and improve hemodynamics by providing a symmetric flow 
pattern, have shown a primary patency of 83% at 90 days 212. This primary patency rate was 
higher compared to other similarly published studies 213. 
6. Future perspectives: new frontiers in research 
In the last decade our knowledge of vascular access dysfunction has significantly evolved.  We 
now understand that the most common pathologic lesion seen in AVF and AVG dysfunction is 
aggressive venous neointimal hyperplasia, and biofilms and fibrin sheaths play a major role in 
CVC infection and dysfunction.  In order to advance the field further, we need to further our 
current understanding of both the clinical and experimental pathways that result in venous 
neointimal hyperplasia and mechanisms that lead to biofilm and fibrin sheath production in 
CVCs by using the advanced technologies and tools in cellular and molecular biology, 
bioengineering, genomics, proteomics, and vascular imaging (ultrasound, computed 
tomography, and magnetic resonance imaging) 65,124,214. Finally, small and large animal models 
of AVF and AVG, which a number of investigators in this field have already developed 
61,93,207,215-217, will play an essential role in “translating” our knowledge of pathophysiologic 
mechanisms in vascular access dysfunction to novel therapies for patients. 
7. Conclusion 
The magnitude and costs of dialysis access dysfunction is clearly evident, and will only 
become magnified in the coming years as the prevalent dialysis population continues to 
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increase.  Only by launching a “translational” research initiative (“from animal to human”) 
can recent advances in the understanding of the mechanisms of neointimal hyperplasia 
formation and vascular stenosis and catheter dysfunction be translated to the development 
of novel effective therapies for patients.  
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